Infection with the hepatitis C virus (HCV) is a significant public health concern associated with a high burden of morbidity and mortality \[[@CIV948C1], [@CIV948C2]\]. Recent estimates suggest that worldwide, of the 185 million individuals infected, over 700 000 people die annually as a result of infection \[[@CIV948C3], [@CIV948C4]\].

The attainment of a sustained virological response (SVR), defined as aviremia 12 or 24 weeks after the completion of antiviral therapy (SVR12 or SVR24), is associated with an improved prognosis compared with patients either untreated or failing therapy. These benefits include improved histology, reduced risk of hepatocellular carcinoma, and improved overall survival \[[@CIV948C5], [@CIV948C6]\].

Despite these benefits, treatment uptake for chronic HCV has been low due to complexities of treatment and poor success rates. The availability of new highly efficacious regimens provides the foundation for marked treatment scale-up; however, high costs are currently limiting access \[[@CIV948C7]\].

One challenge to treatment scale-up is the risk of HCV recurrence, either as late relapse post-SVR or reinfection following treatment. HCV recurrence is a particular concern in patients with ongoing high-risk behaviors, such as injecting drug users (IDUs), who are more susceptible to reinfection, and also patients coinfected with human immunodeficiency virus (HIV) who may be at increased risk of relapse due to their immunocompromised status \[[@CIV948C11]\].

A number of studies have been carried out to examine the durability of treatment-induced SVR in patients with chronic HCV in a variety of patient populations. Our aim was to systematically review the existing evidence and undertake meta-analysis to provide summary estimates of the recurrence rate by risk group. The secondary aim was to evaluate the contribution of late relapse and of reinfection to the recurrence rate. This work fits within the theme one of the PROGRESS framework for prognosis research ("fundamental prognosis research") and will provide a clearer understanding of HCV recurrence to inform the provision of antiviral therapy \[[@CIV948C16]\].

METHODS {#s2}
=======

Search Strategy and Inclusion Criteria {#s2a}
--------------------------------------

The MEDLINE database was searched from 1990 until 1 March 2015 for studies analyzing HCV recurrence post-SVR. A sensitive search string was developed using terms including hepatitis C, treatment, SVR, recurrence, relapse, and reinfection ([Supplementary Appendix](#sup1){ref-type="supplementary-material"}). The reference lists of articles were thoroughly searched to identify additional articles. Lastly, the proceedings of the following conferences were search for additional studies: International Liver Congress (EASL), The Liver Meeting (AASLD), Conference on Retroviruses and Opportunistic Infections, and the International AIDS Conference.

Studies included were to have enrolled adult patients (aged ≥18) who achieved SVR after antiviral treatment for acute or chronic HCV. SVR was defined as undetectable HCV RNA 12 or 24 weeks post-treatment. There was no stipulated method of HCV acquisition or specific antiviral treatment regimen. There were no restrictions on study design however all studies were to have a follow-up longer than 6 months post-SVR. Studies were excluded if they examined rate of recurrence after spontaneous clearance, or if they measured recurrences after the end of treatment, not allowing for the SVR time period to elapse.

Studies were categorized in to 3 groups: (1) Low-risk population, inclusive of studies of mono-HCV infected patients with no recognized risk factors for reinfection; (2) High-risk population, inclusive of studies of mono-HCV infected patients with at least 1 identified risk factor for reinfection; and (3) HIV/HCV coinfection populations, inclusive of all studies of HIV/HCV coinfected persons, regardless of the presence or absence of other risk factors. Risk factors for reinfection were defined as current or former IDU, imprisonment, and men who have sex with men (MSM). Studies of liver transplant recipients were excluded.

Quality Assessment {#s2b}
------------------

Articles meeting the inclusion criteria were assessed for methodological quality using the Newcastle--Ottawa Scale (NOS). The assessment was modified to allocate a maximum of 8 stars, for quality of selection, comparability, exposure, and outcome of study participants ([Supplementary Appendix](#sup1){ref-type="supplementary-material"}). Studies with a NOS rating ≥6 were considered high-quality.

Data Extraction {#s2c}
---------------

The following data were extracted for each study: location, design, recruitment, patient characteristics, average follow-up time, number of HCV recurrences, total PYFU, and frequency of HCV RNA assessment. HCV recurrence was defined as confirmed HCV RNA detectability post-SVR. Where possible, recurrence was characterized as either late relapse or as reinfection, with categorization carried out according to the original study definitions and techniques. In all studies using phylogenetic techniques late relapse was defined as detection of HCV RNA of the same virus lineage and reinfection as identification of a different virus. In the majority of studies, this classification was according to the protocol in the original article. In genotyping studies where no criteria for classification were given, the same definitions were applied by the authors of the current meta-analysis. In some studies, categorization was done by the study authors without confirmatory genotyping. In these studies, the decision to classify as late relapse or reinfection was usually made through consultation with patients to assess for the presence or absence of risk behaviors (eg, injecting drug use, unsafe procedures, etc.).

PYFU were accrued from the SVR time-point; in those studies where follow-up originated at the end-of-treatment, PYFU were appropriately adjusted. If total PYFU was not explicitly stated, it was estimated from the average follow-up time; studies in which PYFU was inestimable were excluded. In the case of study duplications, the article providing the most comprehensive account of the study population and longest follow-up period was used.

The literature search, data extraction, and quality assessment were carried out independently by 2 authors (B. S., J. S.), and any differences were resolved by consensus.

Data Synthesis {#s2d}
--------------

For each study, the incidence rate of HCV recurrence was calculated as the number of recurrences per 1000 PYFU and was reported with the corresponding 95% Wilson confidence interval (95% CI). Given the rarity of events, estimates were transformed using the Freeman-Tukey double arcsine transformation \[[@CIV948C17], [@CIV948C18]\]. A pooled estimate for recurrence was then calculated for each of the three groups separately using a random-effects model \[[@CIV948C19]\]. In addition, meta-analyses of the rate of late relapse and of the rate of reinfection were carried out including studies providing this data. The pooled estimates were used to calculate the 5-year event rate for recurrence, late relapse, and reinfection for each population. The summary 5-year risk was calculated using 1 -- (1 -- pooled incidence rate)^5^ and as such assumed that the pooled rate of recurrence was constant over the follow-up duration. For each calculation, the degree of heterogeneity between studies was quantitatively assessed using I^2^ and tau^2^, where an I^2^ ≥ 50% may indicate substantial heterogeneity and ≥75% is indicative of considerable heterogeneity. The existence of publication bias was evaluated by observational analysis of funnel plots. All analyses were conducted using STATA version 13 (StataCorp LP, Texas).

RESULTS {#s3}
=======

As shown in Figure [1](#CIV948F1){ref-type="fig"}, a total of 1180 references were identified and screened for eligibility. Of these, results were available from 59 studies reporting on recurrence post-SVR in a total of 9049 patients. Two studies evaluated two distinct subgroups of monoinfected and HIV coinfected patients and as such were included in 2 analysis groups. Of the studies deemed possibly relevant and screened against inclusion criteria, the main reasons for exclusion were the assessment of recurrence rate after spontaneous clearance and the lack of an SVR time period after the end-of-treatment. The study and cohort characteristics are shown in Table [1](#CIV948TB1){ref-type="table"}. All identified studies evaluated SVR at 24 weeks post-treatment; no studies eligible for inclusion used SVR12 as the endpoint for analysis. Frequency of HCV RNA assessment varied from every 3 months to 1 single assessment during follow-up. For all 3 risk groups, funnel plots appeared symmetrical indicating no evidence of bias. Of all studies, 49/59 (83%) were considered high-quality (NOS score ≥6). The main biases observed were in determining PYFU and in accepting the authors\' opinion regarding reinfection vs relapse.

###### 

Study Characteristics of Included Studies

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study, Year (Ref)                                                Location and Study Design                                      Recruitment and Exclusion Criteria                                                                                                                                           Treatment                          Total With SVR   Mean Age   \% Male   Frequency of HCV RNA Testing                NOS Rating^a^
  ---------------------------------------------------------------- -------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------- ---------------- ---------- --------- ------------------------------------------- ---------------
  Low risk of reinfection                                                                                                                                                                                                                                                                                                                                                                                                           

   Howe et al 2015 \[[@CIV948C20]\]                                Europe, US, and Canada; Long-term FU of RCTs                   Genotype-1 with compensated liver disease enrolled in Phase 2/3 BOC studies                                                                                                  BOC + Peg-IFN + RBV                696              NR         NR        Every 3 mo for 6 mo, then 6 mo              7 (1)

   Koh et al 2013/Hara et al 2014 \[[@CIV948C21], [@CIV948C22]\]   US; Long-term FU of clinical research protocols                Enrolled in clinical research by National Institute of Diabetes and Digestive and Kidney Diseases                                                                            Peg-IFN or IFN ± RBV               103              56         56        Regularly (freq. NR)                        7 (1)

   Manns et al 2013 \[[@CIV948C23]\]                               International; Long-term FU of RCTs                            Enrolled in 2 phase 3 studies; No HBV or HIV coinfection and no active substance abuse                                                                                       Peg-IFN ± RBV\                     366\             46\        62\       Annually (for 5 y)                          6 (0)
                                                                                                                                                                                                                                                                                                               IFN ± RBV                          636              43         63                                                    

   Giordanino et al 2013 \[[@CIV948C24]\]                          Italy; Prospective cohort                                      Consecutive presentation at hepatology clinics; treatment-naive with no decompensation                                                                                       Peg-IFN + RBV                      115              46         60        Every 6 mo for 3 y, then annually           6 (--)

   Hotho et al 2013 \[[@CIV948C25]\]                               The Netherlands; Long-term FU of RCT                           RCT enrolling genotype-1, treatment-naïve and experienced patients                                                                                                           Peg-IFN + RBV + narlaprevir        19               56         74        6 and 18 mo post-SVR                        5 (--)

   Ignatova et al 2013 \[[@CIV948C26]\]                            Russia; NR                                                     NR                                                                                                                                                                           Antiviral treatment                208              37         52        NR                                          5 (0)

   Papastergiou et al 2013 \[[@CIV948C27]\]                        Rhodes, Greece; Prospective cohort                             Consecutive enrolment of treatment-naïve patients in hepatology unit; No HBV or HIV coinfection                                                                              Peg-IFN + RBV                      145              47         60        Annually                                    7 (1)

   Rahman et al 2013 \[[@CIV948C28]\]                              Dhaka, Bangladesh; Prospective cohort                          Enrolment from hospital clinic                                                                                                                                               Peg-IFN + RBV                      52               41         78        Annually                                    5 (0)

   Rutter et al 2013 \[[@CIV948C29]\]                              Vienna, Austria; Long-term FU of clinical research protocols   Enrolment from prospective RCTs and early access programme                                                                                                                   Peg-IFN + RBV + DAA                103              48         67        At least annually                           6 (1)

   Torres Ibarra et al 2013 \[[@CIV948C30]\]                       Mexico; Retrospective cohort                                   Consecutive enrolment from medical centre                                                                                                                                    Peg-IFN or IFN ± RBV               188              43         46        Every 6 mo                                  7 (0)

   Uyanikoglu et al 2013 \[[@CIV948C31]\]                          Turkey; Retrospective cohort                                   Consecutive enrolment from hospital clinic                                                                                                                                   Peg-IFN or IFN ± RBV               196              46         45        Every 6 mo                                  7 (0)

   Li et al 2012 \[[@CIV948C32]\]                                  Chongqing, China; Retrospective cohort                         NR                                                                                                                                                                           Peg-IFN or IFN ± RBV               146              NR         NR        NR                                          5 (0)

   Maruoka et al 2012 \[[@CIV948C33]\]                             Chiba, Japan; Retrospective cohort                             Consecutive enrolment of patients undergoing liver biopsy at hospital; No HBV or HIV coinfection                                                                             IFN therapy                        207              48         66        Every 1--3 mo                               7 (--)

   Choi et al 2011 \[[@CIV948C34]\]                                Busan, Korea; Retrospective cohort                             Consecutive enrolment from hospital clinic                                                                                                                                   Peg-IFN + RBV                      224              48         58        Every 6 mo                                  7 (--)

   Morisco et al 2011 \[[@CIV948C35]\]                             Italy; Prospective cohort                                      Consecutive enrolment from hospital clinics                                                                                                                                  Peg-IFN or IFN ± RBV               150              48         67        Every 6 mo for 3 y, then annually           6 (--)

   Puig-del-Castillo et al 2011 \[[@CIV948C36]\]                   Barcelona, Spain; Retrospective cohort                         Consecutive enrolment from hospital clinics                                                                                                                                  Peg-IFN + RBV                      80               41         70        Single assessment after 5 y                 7 (1)

   Trapero-Marugán et al 2011 \[[@CIV948C37]\]                     Madrid, Spain; Prospective cohort                              Consecutive enrolment from hospital hepatitis clinic; No HIV or HBV coinfection and no alcohol or IDU abuse                                                                  Peg-IFN + RBV                      153              49         54        Annually (for 5 y)                          7 (--)

   da Costa Ferreira et al 2010 \[[@CIV948C38]\]                   São Paulo, Brazil; Retrospective cohort                        Enrolment from hospital hepatitis clinic; No HBV or HIV coinfection                                                                                                          Peg-IFN or IFN ± RBV               174              46         73        Annually                                    7 (0)

   De Jesús et al 2010 \[[@CIV948C39]\]                            Puerto Rico; Retrospective cohort                              Enrolment from hospital clinic                                                                                                                                               Peg-IFN or IFN ± RBV               64               54         98        Single assessment                           6 (0)

   Giannini et al 2010 \[[@CIV948C40]\]                            Genoa, Italy; Prospective cohort                               Consecutive presentation at hospital hepatitis unit; No HIV coinfection and no IDU or alcohol abuse                                                                          Peg-IFN + RBV                      231              44         60        Every 6 mo                                  7 (1)

   Kim et al 2010 \[[@CIV948C41]\]                                 Daejeon, Korea; Retrospective cohort                           Review of medical records from 1 hospital                                                                                                                                    Peg-IFN + RBV                      37               NR         81        NR                                          6 (--)

   Lee et al 2010 \[[@CIV948C42]\]                                 Seoul, Korea; Prospective cohort                               Enrolment from hospital clinic                                                                                                                                               Peg-IFN + RBV                      68               55         62        NR                                          6 (0)

   Morgan et al 2010 \[[@CIV948C43]\]                              US; Long-term FU of clinical research protocols                Enrolled in HALT-C trial; patients with advanced disease and treatment-experience                                                                                            Peg-IFN + RBV                      91               49         76        Single assessment                           5 (1)

   Sood et al 2010 \[[@CIV948C44]\]                                Ludhiana, India; Prospective cohort                            Enrolment from hospital clinic; No HBV or HIV coinfection                                                                                                                    Peg-IFN or IFN + RBV               100              41         78        Annually                                    7 (0)

   Swain et al 2010 \[[@CIV948C45]\]                               Europe, US, and Canada; Long-term FU of RCTs                   Enrolled on to multicentre RCTs; No HBV or HIV coinfection and no alcohol or IDU abuse in past year                                                                          Peg-IFN + RBV\                     1077\            NR\        63\       Annually (for 5 y)                          6 (0)
                                                                                                                                                                                                                                                                                                               Peg-IFN monotherapy                166              NR         60                                                    

   George et al 2009 \[[@CIV948C46]\]                              Madrid, Spain; Prospective cohort                              NR; No HBV or HIV coinfection                                                                                                                                                Peg-IFN or IFN + RBV               147              49         50        Annually                                    7 (--)

   Hofer et al 2009 \[[@CIV948C47]\]                               Vienna, Austria; Retrospective cohort                          Enrolment from hospital clinic                                                                                                                                               Peg-IFN or IFN ± RBV               251              NR         65        NR                                          6 (--)

   Kim et al 2009 \[[@CIV948C48]\]                                 Incheon, Korea; Retrospective cohort                           Enrolment from hospital clinic                                                                                                                                               Peg-IFN or IFN ± RBV               73               47         36        NR                                          6 (0)

   Maylin et al 2008 \[[@CIV948C49]\]                              Clichy, France; Retrospective cohort                           Enrolment from hospital and follow-up in outpatient clinic                                                                                                                   Peg-IFN or IFN ± RBV               344              45         69        Annually                                    7 (--)

   Adamek et al 2007 \[[@CIV948C50]\]                              Poland; NR                                                     NR; No HBV or HIV coinfection                                                                                                                                                IFN + RBV                          78               43         64        Single assessment                           5 (--)

   Chavalitdhamrong et al 2006 \[[@CIV948C51]\]                    Bangkok, Thailand; Retrospective cohort                        Enrolment from hospital hepatitis clinic; No HBV or HIV coinfection                                                                                                          IFN therapy                        171              48         90        Every 6--12 mo                              6 (--)

   Ciancio et al 2006 \[[@CIV948C52]\]                             Turin, Italy; Long-term FU of RCT                              Enrolled onto RCT with prior treatment-experience                                                                                                                            Peg-IFN + RBV                      97               43         72        Every 6 mo                                  5 (0)

   Desmond et al 2006 \[[@CIV948C53]\]                             Melbourne, Australia; Retrospective cohort                     Enrolment from hospital hepatitis clinic                                                                                                                                     Peg-IFN or IFN ± RBV               147              40         67        Every 6--12 mo                              8 (1)

   Moreno et al 2006 \[[@CIV948C54]\]                              Oviedo, Spain; Retrospective cohort                            Consecutive enrolment at hospital clinic                                                                                                                                     Peg-IFN or IFN ± RBV               132              37         64        NR                                          6 (--)

   Yu et al 2005 \[[@CIV948C55]\]                                  Kaohsiung, Taiwan; Prospective cohort                          Enrolment from hospital clinic; No HBV coinfection                                                                                                                           Peg-IFN or IFN therapy             64               44         47        Annually                                    7 (0)

   Khokhar et al 2004 \[[@CIV948C56]\]                             Islamabad, Pakistan; Prospective cohort                        Enrolment from hospital clinic                                                                                                                                               IFN + RBV                          57               46         NR        Every 6 mo (for 3 y)                        8 (0)

   Tsuda et al 2004 \[[@CIV948C57]\]                               Japan; Retrospective cohort                                    Consecutive enrolment from hospital clinics                                                                                                                                  IFN therapy                        38               51         72        At least every 6 mo                         6 (--)

   Veldt et al 2004 \[[@CIV948C58]\]                               Europe; Long-term FU of clinical research protocols            Consecutive enrolment from European centres, all patients participated in protocolled studies                                                                                IFN monotherapy                    286              41         59        Every 6 mo                                  6 (0)

   Ponsoda Arlettaz et al 2002 \[[@CIV948C59]\]                    Montpellier, France; NR                                        NR                                                                                                                                                                           IFN ± RBV                          125              48         NR        Every 6 mo                                  5 (--)

   Diago et al 2001 \[[@CIV948C60]\]                               Valencia, Spain; Prospective cohort                            NR; Prior treatment experienced                                                                                                                                              IFN + RBV                          19               NR         NR        6 and 18 mo post-SVR                        5 (0)

   Fontaine et al 2000 \[[@CIV948C61-C94]\]                        Paris, France; NR                                              Enrolment from hepatology unit                                                                                                                                               IFN ± RBV                          44               NR         41        Every 6 mo                                  5 (0)

   Marcellin et al 1997 \[[@CIV948C61-C94]\]                       Clichy, France; Prospective cohort (63% from RCTs)             Consecutive enrolment from clinic; No HBV or HIV coinfection                                                                                                                 IFN monotherapy                    75               NR         59        Every 6 mo                                  7 (0)

   Reichard et al 1995 \[[@CIV948C61-C94]\]                        Sweden; Long-term FU of RCT                                    Multicentre enrolment                                                                                                                                                        IFN monotherapy                    14               50         57                                                    6 (0)

  High risk of reinfection (IDUs and prisoners)                                                                                                                                                                                                                                                                                                                                                                                     

   Weir et al 2014 \[[@CIV948C61-C94]\]                            Scotland; Retrospective cohort                                 IDUs identified using Scottish HCV and clinical laboratory data and records                                                                                                  Antiviral treatment                277              NR         NR        One or two assessments                      6 (0)

   Ruzic et al 2013 \[[@CIV948C61-C94]\]                           Vojvodina, Serbia; Retrospective-prospective cohort            IDUs with 1-year abstinence enrolled at infectious disease clinic                                                                                                            Peg-IFN + RBV                      20               30         63        Single assessment after 5-years follow-up   6 (--)

   Hilsden et al 2013 \[[@CIV948C61-C94]\]                         Alberta and Vancouver, Canada; Long-term FU of RCT             Recent IDU or crack cocaine use (within 3 mo); enrolled in to community-based RCT to received treatment or delayed treatment; No HBV or HIV coinfection                      Peg-IFN + RBV                      23               41         91        NR                                          7 (0)

   Edlin et al 2013 \[[@CIV948C61-C94]\]                           New York, US; NR                                               Active IDU enrolled at community based needle exchange program; enrolled both acute and chronic HCV                                                                          Peg-IFN + RBV                      15               36         74        NR                                          5 (0)

   Conway et al 2013 \[[@CIV948C61-C94]\]                          Vancouver, Canada; Prospective cohort                          IDUs treated within multidisciplinary program; enrolled both acute and chronic HCV                                                                                           Peg-IFN + RBV or DAA regimen       70               53         96        At least every 6 mo                         8 (1)

   Deshaies et al 2013 \[[@CIV948C61-C94]\]                        Quebec City, Canada; Prospective cohort                        Active IDU enrolled in community setting (TACTIC project)                                                                                                                    Antiviral treatment                20               39         60                                                    5 (0)

   Grady et al 2012 \[[@CIV948C61-C94]\]                           Amsterdam, The Netherlands; Prospective cohort                 IDUs enrolled in Amsterdam Cohort Studies of drug users                                                                                                                      Peg-IFN + RBV                      42               51         74        Every 6--12 mo                              7 (0)

   Manolakopouos et al 2012 \[[@CIV948C61-C94]\]                   Athens, Greece; Retrospective cohort                           Past and current IDUs enrolled in multidisciplinary supervised program at three liver units                                                                                  Antiviral treatment                61               38         80        Single assessment (mean 2 y post-SVR)       6 (1)

   Grebely et al 2010 \[[@CIV948C61-C94]\]                         Vancouver, Canada; Prospective cohort                          Enrolment at addiction clinics; 54% IDU in previous 6 mo (100% ever IDU); enrolment at community clinics providing addiction services                                        IFN or Peg-IFN + RBV               35               44         96        Annually                                    8 (1)

   Currie et al 2008 \[[@CIV948C61-C94]\]                          San Francisco, US; Prospective cohort                          IDUs part of a larger study; advertisements for enrolment in hospitals, liver and methadone clinics etc.                                                                     Antiviral treatment                9                46         89        Every 6 mo                                  8 (0)

   Backmund et al 2004 \[[@CIV948C61-C94]\]                        Munich, Germany; Prospective cohort                            Opiate-dependent IDUs; enrolled during detoxification treatment                                                                                                              IFN ± RBV                          18               32         61        Annually                                    8 (1)

   Dalgard et al 2002 \[[@CIV948C61-C94]\]                         Oslo, Norway; Prospective long-term FU of RCT                  IDU as route of transmission; abstinent for ≥6 mo                                                                                                                            IFN ± RBV                          27               30         67        NR                                          6 (1)

   Marco et al 2013 \[[@CIV948C61-C94]\]                           Catalonia, Spain; Retrospective cohort                         Prisoners treated in routine clinical practice; 20% with risk factor for reinfection                                                                                         Peg-IFN + RBV                      101              33         97        Annually                                    8 (1)

   Bate et al 2010 \[[@CIV948C61-C94]\]                            Adelaide, Australia; Retrospective cohort                      Incarcerated for entire planned duration of therapy; 55% past/present IDU                                                                                                    IFN or Peg-IFN ± RBV               53               34         95        NR                                          7 (1)

  HIV/HCV coinfected                                                                                                                                                                                                                                                                                                                                                                                                                

   Martin et al 2013 \[[@CIV948C61-C94]\]                          London, UK; Retrospective cohort                               HIV-positive MSM enrolled at HIV clinic; patients excluded if primary mode of transmission was via contaminated blood products or IDU; enrolled both acute and chronic HCV   Antiviral treatment (91% on ART)   114              41         100       NR                                          6 (0)

   Marco et al 2013 \[[@CIV948C61-C94]\]                           Catalonia, Spain; Retrospective cohort                         Prisoners treated in routine clinical practice; 20% with risk factor for reinfection                                                                                         Peg-IFN + RBV (100% on ART)        18               33         98        Annually                                    7 (1)

   Swain et al 2010 \[[@CIV948C45]\]                               Europe, US, and Canada; Long-term FU of RCTs                   HIV-positive enrolled into RCT at different centres                                                                                                                          Peg-IFN ± RBV                      100              NR         82        Annually (for 5 y)                          6 (0)

   Soriano et al 2004 \[[@CIV948C61-C94]\]                         Spain; Retrospective FU of RCTs                                HIV-positive enrolled on 4 different RCTs; no HBV coinfection or active drug or alcohol abuse                                                                                Peg-IFN + RBV (53% on ART)         77               34         68        Regularly (freq. NR)                        7 (--)
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Abbreviations: ART, antiretroviral therapy; BOC, boceprevir; DAA, direct acting antiviral; FU, follow-up; HALT-C, hepatitis C antiviral long-term treatment against cirrhosis; HBV, hepatitis B virus; HCV, hepatitis C virus; HIV, human immunodeficiency virus; IDU, injecting drug user; IFN, interferon; MSM, men who have sex with men; NOS, Newcastle-Ottawa Scale; NR, not reported; Peg-IFN, pegylated-interferon; RBV, ribavirin; RCT, randomized controlled trial; SVR, sustained virological response.

^a^ NOS score is score out of 8; score in brackets is the score for the quality of categorization of recurrence as either late relapse or reinfection, where 1 indicates distinction was based on genotyping, 0 indicates distinction was by author/clinician discretion or no distinction was made, and -- indicates that no recurrences were observed.

![Flow diagram of study selection for systematic review of hepatitis C virus (HCV) recurrence in patients achieving a sustained virologic response after treatment for HCV infection. Low-risk studies include those examining recurrence in general populations and high-risk studies include those studying patients with at least 1 reinfection risk factor (injecting drug use or prison populations). Human immunodeficiency virus (HIV)/HCV coinfected studies include all those of coinfected participants, regardless of risk factors. Total studies in the 3 groups does not equal the total number of studies identified as 2 studies examined 2 populations.](civ94801){#CIV948F1}

Low-risk Population {#s3a}
-------------------

Forty-three articles were found evaluating the risk of recurrence in 7969 low-risk patients. Of these, 29 were prospective or retrospective cohorts, and 10 follow-up patients enrolled in randomized clinical trials (RCTs) or research protocols; study type was not recorded in 4 studies. All studies were carried out in patients with chronic HCV. In 39 studies, patients were treated with peg-IFN or IFN, either in combination with ribavirin or as monotherapy. In 3 studies, treatment consisted of peg-IFN, ribavirin, and a DAA (boceprevir n = 1, narlaprevir n = 1, unspecified n = 1); treatment regimen was not specified in the final study. The mean of the average follow-up post-SVR was 3.9 years (range, 1.0--8.7 years). Of the 28 studies with at least 1 recurrence, 11 used genotyping or sequencing to determine recurrence type, 5 relied on author judgment/terminology, and 12 did not classify the recurrence.

Overall, 108/7969 experienced HCV recurrence with individual study recurrence rates varying from 0.00/1000 PYFU to 70.18/1000 PYFU (Table [2](#CIV948TB2){ref-type="table"}). Following random effects meta-analysis, the pooled estimate for the recurrence rate was 1.85/1000 PYFU (95% CI, .71--3.35; Table [3](#CIV948TB3){ref-type="table"}); however, a high level of heterogeneity was observed (I^2^ = 73.0%). Based on this pooled estimate, the corresponding 5-year recurrence risk was 0.95% (95% CI, .35%--1.69%; Figure [2](#CIV948F2){ref-type="fig"}).

###### 

Hepatitis C Virus Recurrences and Rate of Recurrence in Included Studies

  Study                           Number With SVR   Avg. Follow-up Post-SVR (Total PYFU Post-SVR)   Method                        Recurrences   Recurrence Rate per 1000 PYFU (95% CI)                                               
  ------------------------------- ----------------- ----------------------------------------------- ----------------------------- ------------- ---------------------------------------- ------------------ ------------------------ -----------------------
  Low-risk studies                                                                                                                                                                                                                   
   Howe et al 2015                696               3.4 (2227.2)                                    Sequencing                    3 (0)         1 (1)                                    4                  1.80 (.70--4.61)         
   Koh et al 2014                 103               7.5 (772.5)                                     Genotyping                    3 (3)         0                                        3                  3.88 (1.32--11.36)       
   Manns et al 2013               Peg-IFN ± RBV     366                                             4.1 (1517.1)                  Genotyping    3 (0)                                    2 (2)              5                        3.30 (1.41--7.69)
  IFN ± RBV                       636               4.94 (3141.8)                                   6 (0)                         0             6                                        1.91 (.88--4.16)                            
   Giordanino et al 2013          115               8.7 (1000.5)                                    --                            0             0                                        0                  0.00 (.00--3.82)         
   Hotho et al 2013               19                1.8 (34.2)                                      --                            0             0                                        0                  0.00 (.00--100.98)       
   Ignatova et al 2013            208               4.7 (972.4)                                     None                          --            --                                       3                  3.09 (1.05--9.03)        
   Papastergiou et al 2013        145               5.7 (820.0)                                     Genotyping and risk factors   1 (0)         1 (1)                                    2                  2.44 (.67--8.85)         
   Rahman et al 2013              52                4.2 (216.0)                                     Terminology                   4 (0)         0                                        4                  18.52 (7.22--46.64)      
   Rutter et al 2013              103               1.8 (180.3)                                     Genotyping and sequencing     2 (2)         0                                        2                  11.09 (3.05--39.54)      
   Torres Ibarra et al 2013       188               5.8 (1081.0)                                    None                          --            --                                       3                  2.78 (.94--8.13)         
   Uyanikoglu et al 2013          196               2.8 (547.2)                                     Terminology                   2 (0)         0                                        2                  3.65 (1.00--13.23)       
   Li et al 2012                  146               1.5 (219.0)                                     None                          --            --                                       7                  31.96 (15.57--64.50)     
   Maruoka et al 2012             207               7.5 (1552.5)                                    --                            0             0                                        0                  0.00 (.00--2.47)         
   Choi et al 2011                224               1.5 (336.0)                                     --                            0             0                                        0                  0.00 (.00--11.30)        
   Morisco et al 2011             150               8.6 (1290.0)                                    --                            0             0                                        0                  0.00 (.00--2.97)         
   Puig-del-Castillo et al 2011   80                5.0 (400.0)                                     Genotyping                    1 (0)         0                                        1                  2.50 (.44--14.02)        
   Trapero-Marugán et al 2011     153               6.3 (969.0)                                     Genotyping                    0             0                                        0                  0.00 (.00--3.95)         
   da Costa Ferreira et al 2010   174               3.9 (681.5)                                     None                          --            --                                       1                  1.47 (.26--8.26)         
   De Jesús et al 2010            64                2.6 (164.8)                                     Risk factors                  1 (0)         0                                        1                  6.07 (1.07--33.57)       
   Giannini et al 2010            231               3.1 (725.7)                                     Genotyping and risk factors   2 (2)         0                                        2                  2.76 (.76--9.99)         
   Kim et al 2010                 37                1.0 (37.0)                                      --                            0             0                                        0                  0.00 (.00--94.06)        
   Lee et al 2010                 68                1.6 (108.8)                                     None                          --            --                                       5                  45.96 (19.79--103.09)    
   Morgan et al 2010              91                6.6 (596.1)                                     Genotyping                    1 (0)         0                                        1                  1.68 (.30--9.44)         
   Sood et al 2010                100               3.0 (301.0)                                     None                          --            --                                       8                  26.58 (13.53--51.56)     
   Swain et al 2010               Peg-IFN + RBV     1077                                            3.8 (4079.1)                  None          --                                       --                 9                        2.21 (1.16--4.19)
  Peg-IFN mono                    166               4.6 (760.5)                                     --                            --            2                                        2.63 (.72--9.54)                            
   George et al 2009              147               4.6 (673.3)                                     --                            0             0                                        0                  0.00 (.00--5.67)         
   Hofer et al 2009               251               4.2 (1054.2)                                    --                            0             0                                        0                  0.00 (.00--3.63)         
   Kim et al 2009                 73                1.4 (103.1)                                     None                          --            --                                       1                  9.70 (1.71--52.91)       
   Maylin et al 2008              344               3.3 (1258.5)                                    --                            0             0                                        0                  0.00 (.00--3.04)         
   Adamek et al 2007              78                1.8 (142.4)                                     --                            0             0                                        0                  0.00 (.00--26.27)        
   Chavalitdhamrong et al 2006    171               2.4 (418.6)                                     --                            0             0                                        0                  0.00 (.00--9.09)         
   Ciancio et al 2006             97                7.2 (695.2)                                     Terminology                   11 (0)        0                                        11                 15.82 (8.86--28.11)      
   Desmond et al 2006             147               2.3 (338.1)                                     Genotyping and risk factors   1 (0)         0                                        1                  2.96 (.52--16.56)        
   Moreno et al 2006              132               3.0 (396.0)                                     --                            0             0                                        0                  0.00 (.00--9.61)         
   Yu et al 2005                  64                6.8 (435.8)                                     Genotyping                    --            --                                       1                  2.29 (.41--12.88)        
   Khokhar et al 2004             57                3.0 (171.0)                                     None                          --            --                                       5                  29.24 (12.55--66.61)     
   Tsuda et al 2004               38                5.7 (216.6)                                     Genotyping                    0             0                                        0                  0.00 (.00--17.43)        
   Veldt et al 2004               286               4.4 (1225.5)                                    Terminology                   12 (0)        0                                        12                 9.79 (5.61--17.04)       
   Ponsoda Arlettaz et al 2002    125               1.2 (145.8)                                     --                            0             0                                        0                  0.00 (.00--25.67)        
   Diago et al 2001               19                1.5 (28.5)                                      None                          --            --                                       2                  70.18 (19.46--223.00)    
   Fontaine et al 2000            44                1.2 (53.9)                                      None                          --            --                                       1                  18.55 (3.28--97.88)      
   Marcellin et al 1997           75                3.5 (250.1)                                     None                          --            --                                       1                  4.00 (.71--22.30)        
   Reichard et al 1999            26                4.9 (127.4)                                     Genotyping                    2 (0)         0                                        2                  15.70 (4.32--55.43)      
  High-risk studies                                                                                                                                                                                                                  
   Weir et al 2014                277               4.5 (410.0)                                     Terminology                   0             7 (0)                                    7                  17.07 (8.29--34.82)      
   Ruzic et al 2013               20                5 (100.0)                                       --                            0             0                                        0                  0.00 (.00--36.99)        
   Hilsden et al 2013             23                1.8 (35.5)                                      Risk factors                  0             1 (0)                                    1                  28.17 (4.99--143.49)     
   Edlin et al 2013               15                NR (45.1)                                       Terminology                   0             1 (0)                                    1                  22.17 (3.92--115.43)     
   Conway et al 2013              70                2.0 (138.6)                                     Genotyping                    0             4 (4)                                    4                  28.86 (11.28--71.85)     
   Deshaies et al 2013                              20                                              1.6 (31.7)                    Genotyping    0                                        2 (1)              2                        63.09 (17.48--203.15)
   Grady et al 2012               42                2.0 (110.6)                                     Sequencing                    0             1 (0)                                    1                  9.04 (1.60--49.45)       
   Manolakopouos et al 2012       61                2.0 (122.0)                                     Genotyping                    0             5 (4)                                    5                  40.98 (17.63--92.36)     
   Grebely et al 2010             35                2.0 (62.5)                                      Genotyping and risk factors   0             2 (1)                                    2                  32.00 (8.82--109.38)     
   Currie et al 2008              9                 3.6 (38.0)                                      Terminology                   0             1 (0)                                    1                  26.32 (4.66--134.95)     
   Backmund et al 2004            18                2.8 (48.8)                                      Genotyping                    0             1 (1)                                    2                  40.98 (11.31--137.65)    
   Dalgard et al 2002             27                4.9 (118.0)                                     Genotyping                    0             1 (1)                                    1                  8.47 (1.50--46.45)       
   Marco et al 2013               101               1.4 (148.5)                                     Genotyping and risk factors   0             6 (5)                                    6                  40.40 (18.65--85.34)     
   Bate et al 2010                53                3.4 (180.4)                                     Genotyping                    5 (5)         4 (4)                                    9                  49.89 (26.47--92.08)     
  HIV/HCV coinfected                                                                                                                                                                                                                 
   Martin et al 2013              114               1.6 (224.3)                                     Terminology                   0             27 (0)                                   27                 120.37 (84.06--169.47)   
   Marco et al 2013               18                NR (22.4)                                       Genotyping and risk factors   0             3 (2)                                    3                  133.93 (46.62--328.41)   
   Swain et al 2010               100               4.0 (398.3)                                     Risk factors                  0             1                                        1                  2.51 (.44--14.08)        
   Soriano et al 2004             77                4.3 (333.7)                                     --                            0             0                                        0                  0.00 (.00--11.38)        

Entries marked with a dash gave no indication whether the recurrence was a late relapse or a reinfection.

Number of late relapses plus number of reinfections does not always equal the total number of cases if the description of certain cases was not provided.

Abbreviations: CI, confidence interval; HCV, hepatitis C virus; HIV, human immunodeficiency virus; NR, not reported; Peg-IFN, pegylated-interferon; PYFU, person-years of follow-up; RBV, ribavirin; SVR, sustained virologic response.

^a^ Number of suspected late relapses (no. confirmed by genotyping or sequencing).

^b^ Number of suspected reinfections (no. confirmed by genotyping or sequencing).

^c^ Total number of late relapses and reinfections.

###### 

Meta-analysis of Recurrence

  Studies                    Subgroup                No. of Studies         Pooled Estimate of Recurrence/1000 PYFU (95% CI)   Heterogeneity (I^2^, *P* Value)
  -------------------------- ----------------------- ---------------------- -------------------------------------------------- ---------------------------------
  Low-risk                                                                                                                     
   All studies               All                     43 (45)^a^             1.85 (.71--3.35)                                   73.0%; .0039
   Sensitivity analysis      High-quality (NOS ≥6)   33 (35)^a^             1.54 (.56--2.85)                                   69.3%; .0028
   Meta-analysis subgroups   Late relapse            31 (32)^b^             0.82 (.08--2.05)                                   67.3%; .0028
  Reinfection                31 (32)^b^              0.00 (.00--.00)        0.0%; .0000                                        
  High-risk                                                                                                                    
   All studies               All                     14                     22.32 (13.07--33.46)                               27.3%; .0035
   Sensitivity analysis      High-quality (NOS ≥6)   12                     22.03 (12.50--33.65)                               32.0%; .0039
   Meta-analysis subgroups   Late relapse            14                     0.00 (.00--1.72)                                   0.0%; .0000
  Reinfection                14                      19.06 (11.42--28.16)   10.5%; .0011                                       
  All IDU studies            12                      16.99 (8.61--27.41)    13.8%; .0017                                       
  All prisoner studies       2                       45.48 (24.95--71.32)   92.2%; --                                          
  HIV/HCV coinfected                                                                                                           
   All studies               All                     4                      32.02 (.00--123.49)                                96.0%; .1095
   Sensitivity analysis      High-quality (NOS ≥6)   4                      32.02 (.00--123.49)                                96.0%; .1095
   Meta-analysis subgroups   Recurrence in cohorts   2                      115.47 (76.58--160.38)                             98.7%; --
  Recurrence in RCTs         2                       0.91 (.005.35)         98.7%; --                                          
  Late relapse               4                       0.00 (.00--.03)        0.0%; .0000                                        
  Reinfection                4                       32.02 (.00--123.49)    96.0%; .1095                                       

Forest Plots of recurrence rates can be found in the [Supplementary Appendix](#sup1){ref-type="supplementary-material"}.

Abbreviations: CI, confidence interval; HCV, hepatitis C virus; HIV, human immunodeficiency virus; IDU, injecting drug user; NOS, Newcastle--Ottawa Scale; PYFU, person-years of follow-up; RCT, followed-up from randomized controlled trial.

^a^ Two studies included 2 different treatment groups.

^b^ One study included 2 different treatment groups.

![Summary 5-year risk (95% confidence interval) of recurrence post-sustained virological response (SVR), by risk group. Presented are the pooled estimates for the 5-year risk of recurrence after achieving an SVR. Also shown are the number of studies that were included to derive each estimate. Abbreviations: HCV, hepatitis C virus; HIV, human immunodeficiency virus.](civ94802){#CIV948F2}

The pooled estimate was 0.82/1000 PYFU (95% CI, .08--2.05) for late relapse, and 0.00/1000 PYFU (95% CI, .00--.00) for reinfection (Table [2](#CIV948TB2){ref-type="table"}). These estimates led to 5-year late relapse and reinfection rates of 0.40% (95% CI, .35%--1.05%) and 0.00% (95% CI, .00%--.00%), respectively (Figure [2](#CIV948F2){ref-type="fig"}).

High-risk Population {#s3b}
--------------------

In total, 14 articles were found that assessed HCV recurrence in high-risk patients. Of these studies, 12 evaluated the risk in IDUs (n = 617) and 2 in prisoners (n = 154). In sum, 10 of 12 IDU studies were cohorts, and 2 were the long-term follow-up from RCTs. Both studies of prisoners were retrospective cohorts of patients receiving treatment while under detention. Twelve of the studies were conducted in patients with chronic HCV exclusively, and 2 studies enrolled patients with acute and chronic HCV. Patients received peg-IFN or IFN with or without ribavirin in 9 studies and either peg-IFN plus ribavirin or a DAA regimen in 1 study; 4 studies did not specify the antiviral regimen. The average of the mean follow-up post-SVR was 2.8 years (range 1.4--4.9 years). Overall, 9/13 studies with at least 1 recurrence used genotyping to classify the recurrence type.

In total, 42 recurrences were observed in a total of 771 patients. The recurrence rate varied from 0.00/1000 PYFU to 63.09/1000 PYFU in each study (Table [2](#CIV948TB2){ref-type="table"}); the pooled estimate for recurrence was 22.32/1000 PYFU (95% CI, 13.07--33.46) and a low level of heterogeneity was observed (I^2^ = 27.3%; Table [3](#CIV948TB3){ref-type="table"}). As shown in Figure [2](#CIV948F2){ref-type="fig"}, this estimate led to a 5-year recurrence rate of 10.67% (95% CI, 6.38%--15.66%) and was driven mainly by reinfection (19.06/1000 PYFU, 95% CI, 11.42--28.16) rather than late relapse.

HIV/HCV Coinfected Population {#s3c}
-----------------------------

Of the 4 studies identified assessing recurrence in the HIV/HCV coinfected patients, 1 was carried out exclusively in MSM, 1 enrolled incarcerated patients only, and the remaining 2 recruited a mixed population. Two studies were cohort studies (n = 132) and two (n = 177) were long-term follow-up of RCTs. Three of the studies enrolled patients with chronic HCV, and the remaining study enrolled patients with both acute and chronic disease. Patients received peg-IFN or IFN with or without ribavirin in 3 studies; 1 study did not specify the regimen. In sum, 3 of the 4 studies reported the proportion of patients receiving antiretroviral therapy for HIV infection. In total, 78% of patients were receiving treatment ranging from 53% to 100% in the 3 studies. Of the 4 studies, 2 excluded patients with active IDU, and 2 enrolled patients with either a history of IDU or drug use during or after treatment. The average of the mean follow-up post-SVR was 3.3 years (1.6--4.3 years). One of the 3 studies reporting at least 1 recurrence used genotyping techniques to classify the recurrence.

Overall, 31/309 patients experienced a recurrence for a pooled recurrence rate of 32.02/1000 PYFU (95% CI, .00--123.49; Table [3](#CIV948TB3){ref-type="table"}); however, a substantial level of heterogeneity was observed and individual study recurrence rates varied from 0.00 to 133.93/1000 PYFU. The pooled rate led to a 5-year recurrence rate of 15.02% (95% CI, .00%--48.26%; Figure [2](#CIV948F2){ref-type="fig"}).

By recurrence type, the pooled estimate for late relapse was 0.00/1000 PYFU (95% CI, .00--.03) and for reinfection it was 32.02/1000 PYFU (95% CI, .00--123.49), leading to a 5-year risk of 0.0% (95% CI, .0%--.01%) and 15.02% (95% CI, .00%--48.26%), respectively. The uncertainties of the reinfection estimate are reflected by the wide 95% CI and the high level of heterogeneity observed.

To attempt to understand the heterogeneity, an analysis of RCTs compared with unselected patient cohorts was conducted. The pooled estimate of recurrence was significantly lower for patients followed-up after RCTs, leading to a significantly lower 5-year recurrence rate compared to the unselected cohorts (0.46% \[95% CI, .00--2.65\] vs 45.86% \[95% CI, 32.86--58.27\]). These data however should be interpreted with caution given the small number of studies available for evaluation (2 studies in each group) and the substantial between study heterogeneity observed (I^2^ = 98.7%).

DISCUSSION {#s4}
==========

Achieving SVR substantially reduces the risk of hepatocellular carcinoma, cirrhosis, and mortality, however these benefits are lost following recurrent infection \[[@CIV948C61-C94]\]. In this meta-analysis, the risk of HCV recurrence after treatment-induced SVR was found to be 1.85/1000 PYFU in the low-risk group and rose to 22.32 and 32.02/1000 PYFU in the high-risk and HIV/HCV coinfection populations, respectively. These incidence rates led to estimated 5-year recurrence rates of 0.95%, 10.67%, and 15.02% in the low-risk, high-risk, and coinfection groups, respectively. Thus, despite higher recurrence rates in those with identified ongoing risk behaviors and/or HIV infection, SVR is durable, and the great majority of patients have SVR at 5 years post-treatment.

The current analysis suggests that the greater recurrence risk in the high-risk and HIV coinfected populations is driven by an increased likelihood of reinfection, highlighting the need for prevention campaigns targeted at individuals who continue to place themselves at high-risk of HCV re-exposure. According to the inclusion criteria, the meta-analysis evaluated the risk of recurrence post-treatment. Consequently, studies evaluating spontaneous cleared were excluded \[[@CIV948C61-C94]\]. The data from these studies support the notion that the risk of recurrence is driven by reinfection in those with high-risk behaviors \[[@CIV948C61-C94], [@CIV948C61-C94]\].

Included studies reported contradictory results about the risk of HCV recurrence among patients with HIV. There remains a question as to whether higher recurrence rates in HIV patients are a consequence of HIV and related immune suppression or to the presence of risk behaviors associated with HCV acquisition. Given that RCTs tend to have more restricted inclusion criteria than open cohorts, we compared recurrence between the 2 types of study. Although the number of studies was low, evidence from RCTs suggested a significantly lower recurrence rate than data from open cohorts, supporting the notion that reinfection in these patient groups, rather than an increased propensity to relapse, is the main driver to recurrence \[[@CIV948C45], [@CIV948C61-C94], [@CIV948C61-C94], [@CIV948C61-C94]\].

It is important to highlight that the majority of studies included analyzed recurrence after treatment with interferon-based therapies. The use of such regimens is decreasing in favor of interferon-free regimens, and although there is no evidence to support the notion that recurrence rates may differ with new treatments, it is possible that this will be the case, particularly if the consequences of reinfection are perceived to be low. Thus, collecting prospective data on recurrence rates after treatment with newer therapies is important.

There are a number of limitations to the present study. First, it is likely that a number of spontaneously clearing recurrent infections were missed, leading to an underestimate of recurrence. Evidence indicates that the probability of spontaneously clearing recurrent infection is high, and the duration of spontaneously clearing infection is about one month \[[@CIV948C61-C94]\]. Thus, HCV RNA assessment at intervals of 6--12 months, as was the case in the majority of studies, is unlikely to capture all recurrences. Second, the analysis was limited by the detection and sequencing methods utilized in the original studies. Evidence from more sensitive detection methods indicates that long-term persistence of low levels of HCV RNA is possible \[[@CIV948C61-C94], [@CIV948C61-C94]\]. While the clinical significance is unclear, it suggests that some patients thought to have achieved SVR may still harbor the HCV.

The use of insensitive sequencing methods has particular implications for the late relapse/reinfection subanalysis. Recent evidence with more sensitive deep sequencing techniques suggests that a number of reinfections may be wrongly classified and are actually the emergence of preexisting resistant minority variants rather than reinfection \[[@CIV948C61-C94]\]. Despite this, previous evidence corroborates this analysis showing that late relapse following SVR is rare, occurring in \<1% of mono- and coinfected individuals \[[@CIV948C45]\]. Furthermore, many recurrent cases have good outcomes, in terms of high spontaneous and treatment-induced clearance rates, supporting the mechanism of reinfection with novel susceptible virus, rather than the emergence of resistant low-level variants \[[@CIV948C61-C94]\]. The distinction between late relapse and reinfection is particularly important when the epidemiological differences between risk groups are considered. In some populations, epidemics are concentrated, limiting genetic diversity such that reinfection will likely be with a highly similar strain, and thus will require better techniques to distinguish late relapse from reinfection \[[@CIV948C61-C94]\].

In those studies not utilizing genotyping methods, bias may have been introduced by the tendency of study authors to classify recurrent infection as late relapse vs reinfection. Indeed, the late relapse rate was highest in the low risk group, suggesting recurrences were more likely attributed to late relapse over reinfection, possibly overestimating the relapse rate in this population. Similarly, in high-risk groups, relapse may have been underestimated by the tendency to classify recurrence as reinfection when uncertain. Finally, the estimates of late relapse and reinfection may have been biased by the availability of studies for inclusion in these analyses. Studies not classifying recurrence were excluded meaning that zero event studies were overrepresented in calculations, possibly leading to an underestimate of the true relapse and reinfection rates.

Despite the limitations, the results of the analysis will be helpful to inform treatment scale-up and modeling of strategies, which prioritize different groups for therapy with the ultimate goal of disease eradication. Although the probability of late relapse is low, reinfection in high-risk groups such as IDUs, prisoners, and HIV-positive MSM present both a challenge and an opportunity for epidemic control. As such, strategies to minimize the risk of reinfection in high-risk groups need to be intensified in parallel to introduction of interferon-free regimens in order to curtail onward transmission. The current analysis highlights the notion that estimates from RCTs may underestimate recurrence and emphasizes the need for real-life analyses and an updated analysis once the results of long-term interferon-free studies are available.

Supplementary Material
======================

###### 

Click here for additional data file.
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